Skip to main content
Illustration of a sad young woman with hives on her skin, wearing a white bathing suit

The most devastating CSU stories are often unseen

~50% of patients with chronic spontaneous urticaria (CSU) are symptomatic despite antihistamines—and their true struggles often go unseen.1,2

Unresolved CSU can distress patients in countless ways3

You may see your patients' CSU symptoms, but not always the stories behind them. Watch the videos below to uncover the hidden burden.

Daily Roller Coaster: the ups and downs of CSU 

Based on real patient experiences. A mother with CSU shows how her erratic symptoms are disrupting her day-to-day life and impacting those closest to her.

Itching to Sleep: CSU and sleep problems

Based on real patient experiences. A woman with CSU shares how intense itch is keeping her awake at night and impacting her day-to-day life.

It's Not You, It's My CSU: relationship trouble

Based on real patient experiences. A man with CSU shares how hives is complicating his relationships.

Recipe for Disaster: CSU and work impairment 

Based on real patient experiences. A man with CSU shares how his symptoms are interfering with his work and changing the way people see him.

Uninvited Guest: social impact of CSU

Based on real patient experiences. A woman with CSU shares how hives is impacting her social life.

The unseen burden

It’s not always apparent, but many patients with CSU are stuck in a relentless cycle of sleepless nights, depression, anxiety, and work and school impairment.3

To make a meaningful difference in CSU, we must first recognize the hidden toll it can take on approximately half of patients who are symptomatic despite taking increased doses of antihistamines.1

Real-world evidence shows low satisfaction with CSU treatments4,*

In a US-based real-world study, 35% of health care professionals and 27% of patients reported that they were satisfied with treatment for moderate CSU.4,*

Real-world evidence shows dissatisfaction with CSU treatments. 35% HCPs and 27% of patients reported that they were satisfied with treatment for moderate CSU

*This US-based real-world study assessed the misalignment in patient (n=462) and physician (n=1082) perspectives on the burden of CSU, including 285 physicians and 107 patients reporting treatment satisfaction specifically in patients with moderate CSU severity. Percentages above reflect physicians and patients who reported "satisfied; best result treatment can achieve." An additional 35% of physicians and 40% of patients reported being "satisfied; treatment could do better."4

CSU is a mast cell disease with several internal mediators5

BTK is one key mediator of mast cell degranulation in CSU.5,6

BTK=Bruton's tyrosine kinase; HCP=health care professional.

References:
1. Kaplan A, Lebwohl M, Giménez-Arnau AM, Hide M, Armstrong AW, Maurer M. Allergy. 2023;78(2):389–401. doi:10.1111/all.15603 
2. Goldstein S, Eftekhari S, Mitchell L, et al. Acta Derm Venereol. 2019;99(12):1091–1098. doi:10.2340/00015555-3282 
3. Maurer M, Abuzakouk M, Bérard F, et al. Allergy. 2017;72(12):2005–2016. doi:10.1111/all.13209 
4. Mehlis S, Patil D, Wells MA, et al. Poster presented at: American Academy of Dermatology Annual Meeting 2023; March 17–21, 2023; New Orleans, LA. 
5. Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Nat Rev Dis Primers. 2022;8(1):61. doi:10.1038/s41572-022-00389-z 
6. Mendes-Bastos P, Brasileiro A, Kolkhir P, et al. Allergy. 2022;77(8):2355–2366. doi:10.1111/all.15261